Combination Therapy with Indinavir, Ritonavir, and Delavirdine and Nucleoside Reverse Transcriptase Inhibitors in Patients with HIV/AIDS Who Have Failed Multiple Antiretroviral Combinations

REFERENCES

• Deeks SG, Hellman NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immu-nodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phe-notypic drug susceptibility with virologic outcome. J Infect 0is. 1999;179: 1375–1381.
   Google Scholar
• Shulman NS, Zolopa AR, Passaro DJ, et al. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treat-ment-experienced patients: Clinical and genotypic predic-tors of virologic response. J Acquir Immune Defic Syndr. 2000;23:221–226.
   PubMed Web of Science ®Google Scholar
• Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy: Swiss HIV Cohort Study. AIDS. 1999; 13:F17–F21.
   PubMed Web of Science ®Google Scholar
• Paredes R, Puig T, Arno A, et al. High-dose saquinavir plus ritonavir: Long-term efficacy in HIV-positive protease in-hibitor-experienced patients and predictors of virologic re-sponse. J Acquir Immune Defic Syndr. 1999;22:132–138.
   PubMed Web of Science ®Google Scholar
• Montaner JS, Jahnke N, Hogg R, et al. Multi-drug rescue therapy for HIV-infected individuals with prior virologic fail-ure to multiple regimens: Preliminary results. In: Programs and abstracts of the 38th ICAAC; September 24–27, 1998; San Diego, CA. Abstract 1–201.
   Google Scholar
• Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trial Group Study 359. J Infect Dis. 2000;182:1375–1384.
   PubMed Web of Science ®Google Scholar
• Hammer S, Mellors F, Vaida K, et al. A randomized, pla-cebo-controlled trial of saquinavir, indinavir or nelfinavir in combination with amprenavir, abacavir, efavirenz and adefovir in patients with protease inhibitor failure. In: Pro-grams and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, CA. Abstract LB7.
   Google Scholar
• Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacother. 1999;19(6):708–712.
   PubMed Web of Science ®Google Scholar
• Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569–571.
   PubMed Web of Science ®Google Scholar
• Voorman R, Maio SM, Payne NA, et al. Microsomal me-tabolism of delavirdine: Evidence for mechanism-based inactivation of human cytochrome P4503A. J Pharmacol Exp Ther. 1998;287:381–388.
   PubMed Web of Science ®Google Scholar
• Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome P-4503A-mediated human liver mi-crosomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Discos. 1999;27:902–908.
   PubMed Web of Science ®Google Scholar
• Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH. Role of cytochrome P4503A4 in human metabolism of MK-639, a potent human imunodeficiency virus protease inhibitor. Drug Metab Discos. 1996;24:307–314.
   PubMed Web of Science ®Google Scholar
• Saah A, Winchell G, Seniuk M, Mehrotra D, Deutsch P. Multiple-dose pharmacokinetics and tolerability of indinavir-ritonavir combinations in healthy volunteers. In: Programs and abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, IL. Abstract 362.
   Google Scholar
• Kuritzkes DR, Basset RL, Johnson VA, et al. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: Result of Adult AIDS Clinical Trials Group Proto-col 370. AIDS. 2000;14:1553–1561.
   PubMed Web of Science ®Google Scholar
• Foisy ML, Sommadossi JP. Rapid quantification of indinavir in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B. 1999;721:239–247.
   PubMed Web of Science ®Google Scholar
• Marsh KC, Eiden E, McDonald E. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J Chromatogr B. 1997;704:307–313.
   PubMed Web of Science ®Google Scholar
• Condra JH, Petropoulos CJ, Ziermann R, et al. Drug resis-tance and predicted virologic responses to human immu-nodeficiency virus type 1 protease inhibitor therapy. J In-fect Dis. 2000;182:758–765.
   PubMed Web of Science ®Google Scholar
• Campo R, Suarez G, Miller N, et al. Efficacy of indinavir/ ritonavir-based regimens among patients with prior pro-tease inhibitor failure [abstract]. Antiviral Ther. 2000;5\(suppl 2):6–7.
   Google Scholar
• O'Brien WA, Atkinson TA, Han X, Soya M, East J. Combi-nation therapy with indinavir and ritonavir in antiretroviral-experienced patients. In: Programs and abstracts of the 39th ICAAC; September 26–29, 1999; San Francisco, CA. Abstract 2209.
   Google Scholar
• Johnson D, Andersen D. Norvir plus indinavir plus nevirapine as salvage therapy in a heavily pre-treated HIV-positive population. In: Programs and abstracts of the XIII International AIDS Conference; July 9–14, 2000; Durban, South Africa. Abstract WePeB4172.
   Google Scholar
• Moreno A, Casado JL, Marte-Belda P, et al. Efficacy of the combination of ritonavir plus indinavir plus a nonnucleoside reverse transcriptase inhibitor in patients failing multiple antiretroviral regimens: Pharmacokinetic and resistance data (NIVELPROT Study). In: Programs and abstracts of the XIII International AIDS Conference; July 9–14, 2000; Durban, South Africa. Abstract WePeB4159.
   Google Scholar
• Murphy RL, Sommadossi J-P, Lamson M, et al. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodefi-ciency virus type 1. J Infect Dis. 1999;179:1116–1123.
   PubMed Web of Science ®Google Scholar
• Fiske WD Mayers D, Wagner K, et al. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 in-fected individuals. In: Programs and abstracts of the Fourth Conference of Retroviruses and Opportunistic In-fections; January 22–26, 1997; Washington DC. Abstract 568.
   Google Scholar
• Ferry JJ, Herman BD, Carel BJ, Carlson GF, Batts DH. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. J Acquir Immune Defic Syndr. 1998;18:252–259.
   Web of Science ®Google Scholar